Mold is a type of fungus that has been found on the surface of the earth for millions of years. They can get inside your home through open doors, windows, and air conditioning systems. Inhaling mold spores or coming into contact with mold can have severe adverse effects on your health. Beyond physical symptoms like headache and allergic symptoms, it can have a significant impact on the brain and nervous system. Symptoms may vary, from mild headaches to more severe issues like memory loss or difficulty walking. While it can affect anybody, certain groups like children, the elderly, pregnant women, and those with weakened immune systems are particularly vulnerable to these effects.

How can mold impact your neurological health?

Mold, such as Cladophialophora bantiana, can cause infections in the brain and spinal cord, leading to serious conditions like central nervous system (CNS) infections. While such infections are rare, they can be life-threatening.

Mycotoxins are toxic chemicals produced by certain mold types. These toxins can be released into the air when mold grows indoors, and breathing them in can have direct harmful effects on brain function. Studies indicate that mycotoxins may interfere with the nervous system’s communication pathways, leading to cognitive issues such as memory problems and mood swings.

In fact, long exposure to mold can lead to a variety of neurological symptoms, which can differ depending on an individual’s health and the severity of the mold exposure. Some of them are:

Headaches are one of the most frequent symptoms of mold exposure. While most of the time, these headaches are described as dull, constant, or pressure-like, they can sometimes mimic migraines, accompanied by nausea or sensitivity to light and sound.

Exposure to molds can also trigger seizures. Mold produces toxic substances like mycotoxins that may disrupt the brain’s electrical activity, leading to seizure episodes.

Mold exposure can cause brain fog, which results in concentration, memory, and mental clarity. Studies suggest that mycotoxins can disrupt normal brain function, making it challenging to process information and think clearly.

Exposure to this fungus can also lead to emotional problems. People with this kind of exposure have complained of anxiety, depression, irritability, and sudden mood swings. This could be due to mold toxins interfering with brain chemicals responsible for regulating emotions.

Mold exposure may trigger inflammation, leading to muscle and joint pain. In case of prolonged exposure, it could lead to the development or worsening of fibromyalgia or complex regional pain syndrome (CRPS).

In some cases, mold exposure may lead to tremors, difficulty walking, or problems with muscle coordination. These issues may be linked to mycotoxins affecting the brain or nervous system.

Mold exposure can impact the brain areas responsible for movement and balance, making it harder to stand, walk, or perform fine motor tasks. Individuals may feel unsteady or experience difficulty using devices like phones or computers.

Delirium is a condition wherein a person experiences confusion or disorientation. An abnormal immune response to mold could contribute to this condition. Delirium can make it difficult for individuals to think clearly or understand their surroundings.

Maternal vaccination with the COVID-19 vaccine during pregnancy can be effective against severe disease and hospitalization from the SARS-CoV-2 virus in babies, according to a large study.

The study, published in the journal Pediatrics, revealed that COVID vaccination during pregnancy can protect the children against hospitalization for COVID during the first six months of life.

Amid continuing COVID cases, babies under six months old continue to have one of the highest rates of hospitalization — one in five — due to the COVID virus in the US, as per a 2024 study.

As currently no vaccines against COVID are available for neonates and babies, the American College of Obstetricians and Gynecologists (ACOG) recommends maternal vaccination during pregnancy.

Maternal COVID Vaccination Prevented Other Infections

The retrospective study included 146,031 infants born in Norway between March 2021 and December 2023. Of these, 37, 013 (25 percent) were exposed to COVID-19 vaccination in utero.

The findings showed that babies exposed to the vaccine before birth were no more likely to visit the hospital for overall infections (of any kind) than those whose mothers did not get vaccinated in pregnancy.

However, infants whose mothers were vaccinated were about half as likely to visit the hospital specifically for COVID in their first two months of life compared to babies not exposed to the vaccine in utero.

Among 3 to 5-month-old babies, the risk of a hospital visit for COVID was 24 percent lower in those exposed to the vaccine, but the vaccine's protection against COVID wore off by the time infants were older than 6 months.

Importantly, the mothers' vaccine also prevented the risk of other infections in children.

"There is often an increased risk for a subsequent infection after a viral infection, such as an increased risk of pneumonia after influenza infection, so we wanted to study whether protection against COVID-19 could influence the risk of other infections as well," said lead author Dr. Helena Niemi Eide, from the University of Oslo in Norway, the NPR reported.

"But we found that COVID vaccination in pregnancy protected the infant against COVID and had no apparent effect on other infections," Eide added.

Maternal Vaccine Recommendation in the US

Last week, the American College of Obstetricians and Gynecologists reiterated its recommendation for COVID vaccination during pregnancy.

Despite changes in federal vaccine recommendations due to the US Health Secretary Robert F. Kennedy Jr.’s anti-vaccine stance, the ACOG urged COVID vaccination for

• people who are pregnant,
• recently pregnant,
• considering pregnancy,
• lactating.

Also read: US Judge Blocks RFK Jr.’s Vaccine Schedule, Says Government Ignored Science

"Accumulated safety data from millions of administered doses show no increased risk of adverse maternal, fetal, or neonatal outcomes associated with COVID-19 vaccination in pregnancy,” the ACOG said.

Nipah virus, first identified in 1999, is a serious threat that is 'underestimated' and with its repeated emergence in South and Southeast Asia, it has the potential to turn 'more severe', according to a global team of scientists.

Nipah virus is a zoonotic virus, usually transmitted from animals to humans, but can also be transmitted through contaminated food or directly between people.

In a correspondence published in The Lancet, the scientific team led by the Campus Bio-Medico University of Rome in Italy stated: “the danger of the Nipah virus is in its persistence, that is, it is periodic, lethal, and preventable".

The researchers argued that although the Nipah virus is well understood, there is little action on it, with delays in surveillance, sporadic funding, and episodic preparedness.

“How South and Southeast Asia respond now will determine whether the Nipah virus remains a regional epidemic or if it escalates into something far more severe,” said the experts.

Also read: Why The Nipah Virus Still Persists After 25 Years In Southeast Asia

Recent Nipah Outbreaks In India

According to the Ministry of Health & Family Welfare, two cases of the deadly Nipah virus Disease (NiVD) -- a male nurse from Purba Medinipur district and a female nurse from Mongolkot in Purba Bardhaman district who worked at a private hospital in Barasat in North 24 Parganas district -- were confirmed in West Bengal since last December.

Of these, the 25-year-old female nurse died of cardiac arrest after recovering from Nipah virus infection.

"She died of cardiac arrest this afternoon. Though she had recovered from Nipah infection, she was suffering from multiple complications," a state health department official told PTI in February. The male nurse had recovered and returned home.

Nipah has been endemic to both West Bengal and Keralam (formerly known as Kerala).

The first recorded Nipah outbreak in India occurred in 2001 in West Bengal’s Siliguri, where about 66 cases were reported with high fatality, with significant hospital-based transmission among healthcare workers. Again in 2007, the eastern state’s Nadia district reported an outbreak.

Keralam reported its first Nipah virus outbreak in 2018. The state’s northern districts, Kozhikode and Malappuram, have been on high alert with sporadic and periodic cases occurring in the state in 2019, 2021, 2023, 2024, and 2025.

These cases “are not anomalies and are a reminder of a virus causing recurrent outbreaks for more than two decades, with high mortality, frequent infections of health-care workers, and no approved vaccines or treatments,” said the scientists in the Lancet Correspondence.

Also read: These 24 Pathogens Could Trigger The Next Pandemic, Says UKHSA

What Is The Nipah Virus? How To Prevent?

Nipah is essentially a zoonotic infection -- from animals to humans -- and then from human to human.

The Nipah virus spreads through

• saliva,
• urine,
• other body fluids of an infected person.

The Nipah virus, although rare, is unpredictable. It is not limited to just one part of the body. In severe cases, it can affect multiple organs.

The Lancet paper also highlighted the "lack of diagnostics, protective equipment, and trained personnel" in many facilities in rural and peri-urban areas.

• The researchers suggested
• prioritizing sustained investment
• boosting surveillance,
• improving infection prevention and control,
• decentralizing laboratory capacity,
• One Health implementation,
• regional data sharing,
• accelerated development of vaccines and therapeutics.

“Viruses do not depend on political visibility or public concern to spread; transmission occurs when ecological disruption, delayed detection, and health-system susceptibilities converge,” the experts said.

A new, highly mutated COVID variant called 'Cicada' is spreading in the US. This is the BA.3.2 mutation of the COVID-19 variant. While nationally the cases of COVID have remained low, the BA.3.2 strain is gaining traction across the globe.

What Is The Cicada COVID Variant?

Cicada or the BA.3.2 strain emerged over a year ago, and simmered until last fall. However, this was when it started ramping up in countries including the US. As of February, BA.3.2 has been detected in at least 25 states, noted the US Centers for Disease Control and Prevention (CDC).

The variant's slew of genetic changes in its spike protein is what has made people concerned. This is what makes it unique and distinct from other variants in circulation.

According to Andrew Pekosz, Ph.D., a virologist at the Johns Hopkins Bloomberg School of Public Health, as reported by TODAY.com, "It [the variant] has a lot of mutations that may cause it to look different to your immune system."

The SARS-CoV-2 virus that causes COVID-19 mutates constantly and spreads over time. It thus leads to emergence of new variants.

A new study published in the CDC’s Morbidity and Mortality Weekly Report suggests that emerging variants could weaken protection gained from prior COVID-19 infection or vaccination.

One such “hyper-mutated” strain, BA.3.2, is now being closely tracked by public health officials. In December 2025, the World Health Organization classified it as a “variant under monitoring.”

Read: COVID Variant BA.3.2 Spreads To 23 Countries: Is The Variant Under Monitoring A Cause Of Worry?

When Was Cicada COVID Variant First Detected?

BA.3.2 was first detected in South Africa in November 2024. It is a descendant of BA.3, an Omicron subvariant that appeared in 2022 and briefly circulated alongside BA.1 and BA.2, according to the CDC.

Although BA.3 never became dominant, it did not completely disappear. “It fizzled out, but persisted at low levels,” said Pekosz. After two years and dozens of mutations, BA.3.2 eventually emerged.

For much of 2024, the variant spread quietly, overshadowed by dominant strains like Nimbus and XFG, which stem from BA.2. However, by September, BA.3.2 began gaining ground. “It was under the radar, replicating, until it started spreading more efficiently between people,” Pekosz noted.

What sets BA.3.2 apart is its spike protein, which carries an unusually high number of mutations — around 70 to 75. This makes it significantly different from strains such as JN.1 and LP.8.1, which current COVID-19 vaccines are designed to target.

The CDC describes BA.3.2 as a “genetically distinct” lineage compared to recent variants. Early laboratory studies suggest it may be capable of evading existing immunity, as its spike protein changes help it escape neutralising antibodies.

What Makes Cicada So Unique?

The BA.3.2 variant is nicknamed by T Ryan Gregory, Ph.D., a professor of evolutionary biology at the University of Guelph. He wrote on X, formerly Twitter: "Well, it's that time again. Meet "Cicada", BA.3.2* (including descendant RE.*). This one has been underground for years (its ancestor BA.3 hasn't been circulating since early 2022, and didn't do much then either) but is now emerging as a contender for the next major lineage."

While most of the symptoms of this new variant remains same as from the other variants, one thing that stands out here is the gastrointestinal symptoms that cicada could cause. However, experts note that this variant will not make anyone more sicker. Other symptoms include:

• Cough
• Fever or chills
• Sore throat
• Congestion
• Shortness of breath
• Loss of smell or taste
• Fatigue
• Headache